References
- Hochhaus A, O’Brien SG, Guilhot F, . Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054–1061.
- Kantarjian H, O’Brien S, Cortes J, . Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer 2003;98:81–85.
- Jabbour E, Kantarjian H, O’Brien S, . Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 2006;107:480–482.
- Tantiworawit A, Power MM, Barnett MJ, . Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy. Leuk Lymphoma 2012; 53: 1321–1326.
- Alimena G, Breccia M, Latagliata R, . Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy. Cancer 2006;107:1008–1013.
- Baccarani M, Cortes J, Pane F, . Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041–6051.
- Kantarjian H, Shah NP, Hochhaus A, . Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260–2270.
- Saglio G, Kim DW, Issaragrisil S, . Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362:2251–2259.
- Hughes TP, Hochhaus A, Branford S, . Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010;116: 3758–3765.